NanoVibronix Inc (NAOV) Actualités

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

NanoVibronix Provides Business Update

NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany

Signs Term Sheet for a License and Supply Agreement for Distribution of UroShield NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical...

Form 8-K - Current report

NanoVibronix Signs Letter of Intent with Potential New Distributor

NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface...

NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders

NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan

NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave...

Form 8-K - Current report